---
title: "Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | B Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279423190.md"
description: "Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | B Stock News"
datetime: "2026-03-17T03:40:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279423190.md)
  - [en](https://longbridge.com/en/news/279423190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279423190.md)
generator: "portal-rs"
---

# Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | B Stock News

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | B Stock News

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [CERO.US](https://longbridge.com/en/quote/CERO.US.md)

## Related News & Research

- [SRX Global sells 3,579 Series C preferred shares in private placement valued at $2.86 million](https://longbridge.com/en/news/297369039.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**